Enveric Biosciences Inc Dossier - Source-backed chat

Enveric Biosciences Inc

ENVBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.09

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.46Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $6.5M

Enterprise Value $2.3M

Shares Outstanding 4.5M diluted

Next Earnings Date13 Nov 2026

Last ex-dividend23 Apr 2008

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Enveric Biosciences is a pre-revenue biotechnology company focused on developing next-generation, non-hallucinogenic neuroplastogenic small-molecule therapeutics (such as lead asset EB-003) for neuropsychiatric disorders. While the company has successfully extended its cash runway into Q1 2027 through recent private placements and ATM offerings, it remains a highly speculative micro-cap with ongoing going-concern risks. The streamlined regulatory path recommended by the FDA for EB-003 and strong IP protection are positive drivers, but investors should maintain a Hold stance until the IND is formally cleared and Phase 1 clinical trials begin.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

IND-enabling genotoxicity studies reveal safety concerns, or the FDA places a clinical hold on the EB-003 application. Capital markets tighten, preventing Enveric from raising additional funds, which accelerates going-concern distress and forces highly dilutive equity issuances or a reverse stock split.

Base CaseCentral scenario

$2.0055%

Enveric completes remaining IND-enabling studies for EB-003 and submits the IND application to the FDA in late 2026. The company continues to fund operations through incremental dilution via its ATM facility, maintaining its speculative profile as it prepares for Phase 1 clinical entry.

Bull CaseUpside scenario

$5.0025%

The FDA clears the IND for EB-003 without delay, allowing Enveric to initiate Phase 1 trials by late 2026. The non-hallucinogenic profile of EB-003 is clinically validated, attracting a major pharmaceutical out-licensing partner and securing non-dilutive upfront milestone payments that resolve going-concern issues.

Scenarios reflect our research view at the research date.

Key Investment Merits

Differentiated lead asset (EB-003) designed to promote neuroplasticity without inducing hallucinations, enabling blinded clinical trials and outpatient administration.
Streamlined regulatory path with the FDA recommending direct progression to an IND application, bypassing a formal pre-IND meeting.
Robust intellectual property portfolio (Psybrary™) with recently expanded patent protections and successful defense of key patents (e.g., withdrawal of PGR petition by AbbVie/Gilgamesh).

Key Investment Risks

Substantial going-concern risk with an accumulated deficit of $116.48 million and cash runway only extending into Q1 2027.
High risk of equity dilution due to frequent reliance on private placements, warrant exercises, and At-the-Market (ATM) stock programs to fund operations.
Pre-clinical stage of development with no commercialized products or recurring revenue streams.

Thesis Invalidation Triggers

FDA clinical hold or rejection of the EB-003 IND application.
Inability to secure additional financing before Q1 2027, leading to insolvency or severe restructuring.
Failure to maintain Nasdaq listing requirements, resulting in delisting to OTC markets.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.